TDC
ZYNE

Thompson Davis & Co’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Thompson Davis & Co’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$13K Sell
1,534
-3,591
-70% -$27.6K 0.03% 418
2018
Q2 		$50K Hold
5,125
– – 0.12% 191
2018
Q1 		$45K Hold
5,125
– – 0.12% 182
2017
Q4 		$64K Buy
+5,125
New +$58.7K 0.15% 150

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Thompson Davis & Co's ZYNE Position: Q3 2018 in Review

Thompson Davis & Co reduced its Zynerba Pharmaceuticals, Inc (ZYNE) stake by 70% in Q3 2018, selling an estimated $27.6K and leaving 1,534 shares worth $13K. The position accounts for 0.03% of the portfolio, ranked #418.

Thompson Davis & Co first reported a position in ZYNE in Q4 2017 and has held it in 4 quarters since. The position peaked at $64K in Q4 2017. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2018.

  • Thompson Davis & Co held 1,534 shares of Zynerba Pharmaceuticals, Inc worth $13K as of Q3 2018.
  • Thompson Davis & Co sold 3,591 Zynerba Pharmaceuticals, Inc shares in Q3 2018, an estimated $27.6K.
  • Zynerba Pharmaceuticals, Inc made up 0.03% of Thompson Davis & Co's portfolio in Q3 2018, its #418 holding.
  • Thompson Davis & Co first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and has held it in 4 quarters since.
  • Thompson Davis & Co's Zynerba Pharmaceuticals, Inc position peaked at $64K in Q4 2017.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.